USPTO serial 79307453
HANHUI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 28, 2022
- Examiner
- MUMM, WHITLEY
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HANHUI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christine P. James
Christine P. James Kilpatrick Townsend & Stockton LLP1100 Peachtree Street NE, Suite 2800Mailstop: IP Docketing - 22Atlanta, GA 30309Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in chemotherapy, radiotherapy, endocrine therapy, anesthesia; Pharmaceutical preparations for supplementing vitamins and nutrition, namely, dietary and nutritional supplements; Pharmaceutical preparations for anti-infection and antiviral purposes; Pharmaceutical preparations for improving lactation functions; Pharmaceutical preparations for treating hematological diseases, namely, anemia, leucocyte disorders, blood clots; Pharmaceutical preparations for treating cardiovascular and cerebrovascular diseases, namely, blood lipid disorder, blood pressure disorder, arrhythmia, cardiac insufficiency, angina pectoris, myocardial infarction; Pharmaceutical preparations for treating respiratory system diseases, namely, phlegm, cough, asthma; Pharmaceutical preparations for treating digestive system diseases and disorders, namely, peptic ulcer, diarrhea; Pharmaceutical preparations for treating central nervous diseases and disorders, namely, fever and pain, gout, epilepsy, Parkinsonian syndrome, psychotic disorders, depression, anxiety, mania; Pharmaceutical preparations for treating geriatric diseases, namely, hyperosteogeny, prostatic hyperplasia, senile cataract; Pharmaceutical preparations for treating genitourinary system diseases, endocrine and metabolic system diseases and disorders, allergies, immune system diseases and disorders, liver and gall diseases, Alzheimer's diseases, skin diseases and disorders, obstetric and gynecological diseases and disorders, diseases with eye, ear, nose, mouth, oral cavity, and throat; Chemical preparations for pharmaceutical and medical purposes, namely, antineoplastic drugs, antibiotics, anti-infectives, vitamins and nutritional supplements, anesthetics, and those for treating hematological system diseases, cardiovascular and cerebrovascular diseases, endocrine and metabolic diseases and disorders, respiratory system diseases, digestive system diseases and disorders, central nervous system diseases and disorders, dermatological diseases, obstetric and gynecological diseases and disorders, ophthalmology and otorhinolaryngology diseases, and geriatric diseases; Analgesics; Medicines for humans, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system, eye, ear, mouth, and throat; Sedatives; Tranquillizers; Biological preparations for medical purposes, namely, vaccines, antineoplastic preparations, antitoxin, and antisera; Antibiotics; Injectable pharmaceuticals, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and those for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Tablets, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and tablets for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Bulk medicines, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Biochemical medicines, namely, antineoplastic drugs, anti-infectives, antibiotics, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, and central nervous system; Blood for medical purposes; Herbal tinctures for medical purposes; Diagnostic preparations for medical purposes; Chemical reagents for medical or veterinary purposes; Radium for medical purposes; Radioactive substances for medical purposes; Isotopes for medical purposes; Radioactive medicines for medical imaging and the treatment of tumor and thyroid diseases; Oxygen for medical purposes; Chemical conductors for electrocardiograph electrodes; Semen for artificial insemination; Disinfectants for hygiene purposes; Disinfectants; Solutions for contact lenses; Contact lens cleaning preparations; Media for bacteriological cultures; Bouillons for bacteriological cultures; Bacteriological culture mediums; Nutritive substances for microorganisms for medical purposes; Cultures of microorganisms for medical and veterinary use; Disinfectant wipes; Wadding for medical purposes; Food for babies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Hanhui Pharmaceuticals Co., Ltd.
- Other trademarks owned by Hanhui Pharmaceuticals Co., Ltd.
- Other trademarks owned by Hanhui Pharmaceuticals Co., Ltd.
- Other trademarks in Class 005
- Similar marks named HANHUI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 9, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 1, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 6, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 6, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 28, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 21, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 28, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 28, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 12, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 12, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 23, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 8, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 8, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 8, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 8, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 8, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 3, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 2, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 2, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 28, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 28, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 28, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jan 28, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 28, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 28, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 20, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 28, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 28, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 24, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 23, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 19, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 30, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 26, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 25, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |